How Measles Is Making a Comeback in Europe

The most revealing measles statistic in Europe is a rise followed by a fall. Across the World Health Organization's European Region, which includes 53 countries in Europe and Central Asia, 127,350 cases were reported in 2024. That was twice the 2023 total and the highest number since 1997 [1]. Within the European Union and European Economic Area, the increase was even steeper: 35,212 cases in 2024, almost ten times the 3,973 reported a year earlier [2]. Then the EU and EEA total fell to a preliminary 7,655 in 2025 [3].

A falling curve can look like a solved problem. Measles makes that interpretation dangerous. The 2024 surge showed that Europe had accumulated enough susceptible people for an imported infection to become a large outbreak. The lower 2025 total showed that outbreaks can be interrupted through vaccination, public-health response and the natural exhaustion of local chains. It did not prove that the underlying gaps had closed. By May 2026, transmission in the EU and EEA was still predominantly local [4].

Measles is a respiratory infection caused by a virus that spreads through the air. Fever, cough, a runny nose and inflamed eyes often precede the characteristic rash. The virus is so contagious that a single case can expose many susceptible people in a household, school, clinic or other crowded indoor space. Public-health agencies aim for at least 95 per cent coverage with two doses of a measles-containing vaccine in every community because lower coverage leaves room for sustained transmission [5]. The phrase every community is crucial. A national average cannot stand between a virus and an under-vaccinated neighbourhood.

Vaccination changed the scale of measles so thoroughly that its return can feel surprising. Before widespread immunisation, repeated epidemics were a normal feature of childhood. The combined measles, mumps and rubella vaccine, or MMR, uses weakened viruses that stimulate immune memory without causing those diseases in people eligible to receive it. WHO Europe estimates one dose is about 95 per cent effective against measles and two doses about 99 per cent effective [5]. The second dose mainly gives another chance to the small share of people who did not respond adequately to the first.

Elimination does not mean erasing the virus from the planet. In public health, measles elimination means ending continuous local transmission in a defined area for at least 12 months while maintaining good surveillance. An infected traveller can still bring the virus into an eliminating country. If nearly everyone around that traveller is immune, the chain ends. If susceptible people are clustered together, the virus finds a route onward. Europe has repeatedly moved between these two conditions.

The pandemic widened the route. COVID-19 disrupted routine immunisation appointments and catch-up services, while families moved and health systems diverted staff. Some children who missed a scheduled dose were reached later; others remained susceptible. Those missed cohorts accumulated year after year. In 2024, second-dose measles vaccine coverage in the WHO European Region was 91 per cent, down from 92 per cent in 2019 and short of the 95 per cent target. More than half of the region's countries missed the target for MMR or the combined diphtheria, tetanus and pertussis vaccine; almost one third reported coverage below 90 per cent [6].

The regional percentage conceals a much wider spread. Countries reported very different levels of first-dose coverage, and variation within countries can be larger still. Access can break down for practical reasons: appointments may be scarce, records fragmented, opening hours inflexible or families repeatedly displaced. Conflict has damaged routine services in parts of the region. Some communities face language barriers or distrust rooted in poor treatment by institutions. Vaccine misinformation adds another obstacle, but treating every missed dose as a change of belief mistakes a delivery problem for an argument.

Measles takes advantage of delay. A child scheduled for vaccination at a particular age does not instantly become unreachable after a missed appointment, but the period without protection lengthens. A catch-up campaign can close that gap if it finds the right children. Generic publicity may raise awareness while missing those who cannot navigate the service. Effective programmes use local records, schools, primary care and trusted community organisations to identify who is unprotected and make vaccination convenient.

The 2024 numbers also show the human cost of describing measles as a routine rash. Children under five accounted for more than 40 per cent of cases in the WHO European Region, and more than half of all reported cases required hospitalisation. Thirty-eight deaths had been reported when WHO and UNICEF released their preliminary analysis in March 2025 [1]. Hospitalisation practices and reporting differ across countries, so those proportions should not be read as a single clinical probability for every infected person. They do show that the surge placed a substantial burden on families and health services.

Complications include pneumonia and inflammation of the brain. Infants, pregnant people and those with weakened immune systems can face especially serious disease. A rare, fatal neurological condition called subacute sclerosing panencephalitis can emerge years after infection [5]. Measles also damages immune memory. In a study that compared blood from unvaccinated children before and after measles, investigators found losses in antibodies against many other pathogens. They supported the finding with experiments in macaques [7]. This immune amnesia is an additional reason that recovery from the rash is not necessarily the end of the biological cost.

MMR vaccination does not produce that loss of immune memory [7]. The distinction matters because public discussion sometimes weighs the discomfort or rare adverse effects of vaccination against an idealised version of natural infection. The relevant comparison is with the actual virus, including its complications and its ability to suppress defences built through earlier infections or vaccinations. Safety monitoring continues because no medical intervention is entirely without risk, but the evidence base for MMR spans decades and hundreds of millions of doses.

Why did reported cases fall so sharply after 2024? There is no single European experiment that can assign a percentage of the decline to each cause. Outbreak responses vaccinated susceptible people and interrupted transmission. Awareness improved case finding and encouraged catch-up. Large local outbreaks also eventually encounter fewer susceptible contacts. Seasonality matters because measles transmission often rises in late winter and spring. Changes in reporting can shift totals. The 2025 decline is real in surveillance data, while the contribution of each mechanism remains uncertain.

The latest figures sharpen that caution. In the 12 months from June 2025 through May 2026, EU and EEA countries reported 2,928 measles cases, of which 84.5 per cent were laboratory confirmed. Three quarters of cases with known age and vaccination status were unvaccinated. Only 8.9 per cent of all cases were recorded as imported, while 74 per cent were locally acquired and the remainder were import-related or of unknown origin [4]. Europe was seeing fewer cases than at the 2024 peak, but established community transmission had not vanished.

Surveillance itself has limits. The WHO European Region is geographically larger than the EU and EEA, so their totals should never be compared as though they count the same countries. Case definitions and the completeness of reporting vary. Recent months can rise after delayed reports arrive. Mild cases may be missed; rash illnesses can also be wrongly suspected until laboratory testing rules them out. ECDC therefore combines possible, probable and confirmed cases in its monthly presentation, while marking confirmation status and warning that data may be revised [4].

Laboratories do more than confirm a diagnosis. By reading sections of the viral genome, they can group measles viruses into genotypes and compare closely related sequences. Genomic evidence can connect cases that lack an obvious epidemiological link, or show that apparently simultaneous outbreaks came from separate introductions. Because measles viruses of the same genotype can circulate across many countries, a sequence cannot by itself reconstruct who infected whom. It becomes useful when combined with travel history, dates and contact tracing.

Clinicians occupy the first link in that chain. In a place where measles became rare, a practitioner may never have seen a case. Early symptoms resemble other respiratory infections, and the rash appears later. If a potentially infectious patient spends time in a crowded waiting room, one missed diagnosis can create a difficult tracing exercise. ECDC's threat assessment advises high clinical awareness, rapid isolation, testing and prompt notification, alongside efforts to close immunity gaps [8]. Those measures protect people who cannot be vaccinated as well as those whose doses were missed.

Contact tracing reveals the operational cost of every delay. Teams must identify people who shared air with a case during the infectious period, determine who has evidence of immunity and advise those at high risk. Schools and clinics may need rapid risk assessments while laboratories process specimens. These measures can contain a chain, but they consume time that routine immunisation could have saved. Prevention looks quiet on a budget sheet because the phone calls, specimen runs, isolation decisions and anxious waiting never occur.

Travel supplies the sparks for some outbreaks; clustered susceptibility supplies the fuel. A mobile continent will continue to receive measles introductions while the virus circulates elsewhere. Border controls cannot replace immunity. The deciding condition is what the virus finds after arrival: a wall of vaccinated contacts, or a connected group of susceptible people. This is why a country can report high average coverage and still experience an outbreak in one city, religious community or underserved population.

The response must therefore be both universal and precise. Universal means a reliable routine offer, free or affordable, recorded accurately and available throughout childhood and adulthood for people who missed it. Precise means directing extra staff and outreach to places where records show a gap, then working with communities to understand why it exists. A campaign that raises a national percentage while leaving the least protected cluster untouched may improve a dashboard without removing the route of transmission.

There is also a danger in allowing the exceptional 2024 peak to become the new benchmark. If success means only staying below 35,212 annual EU and EEA cases, persistent transmission can appear reassuringly small. The proper comparison is the elimination goal and the preventability of each chain. In February 2026, ECDC noted that preliminary 2025 cases remained almost twice the 2023 total and that eight people had died [3]. Progress and risk can occupy the same sentence.

Europe's measles comeback arose because protection failed to reach everyone, twice, on time. The virus exposed gaps that had accumulated quietly through disrupted services, uneven access, fragile records and delayed catch-up. Its retreat after 2024 shows that public-health action works. Its continued local spread shows what remains. Measles needs only a narrow passage through a population. Closing that passage requires looking past the continental curve to the people and connected communities missing from the average.